Eli Lilly reported jaw-dropping Phase 3 data showing its triple-agonist retatrutide produced mean weight losses approaching 29% in a late-stage study, while trial documents and follow-up reports flagged higher-than-expected discontinuation rates and tolerability issues. The company disclosed the high-dose efficacy at 68 weeks alongside symptomatic improvements in osteoarthritis pain, prompting industry debate over benefit–risk and market positioning. These results, shared in company briefings and at major industry meetings, put retatrutide among the most potent obesity candidates to date. Independent analysts and clinicians noted the magnitude of weight loss could reset payer and competitive expectations, but they also cautioned that discontinuations and adverse-event profiles will shape real-world uptake and label strategy. Investors and competitors are already recalibrating pipelines and trial designs. Clinicians will focus on subgroup safety data and discontinuation drivers as sponsors prepare regulatory filings and post-marketing strategies. For drug developers, the retatrutide readout underscores how efficacy breakthroughs can simultaneously raise commercial and clinical-management questions.